Statement Of Deviation & Variation
Filed with BSE · · 3 pages · English
Summary by 6ix AI
This filing is a statement of deviation and variation regarding the use of proceeds raised through a preferential issue by Venmax Drugs & Pharmaceuticals Ltd. The statement was reviewed by the Audit Committee and is enclosed as Annexure A. The report details the funds raised and their utilization status, confirming compliance with the original objectives.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sub: Statement of deviation or variation in the use of proceeds raised through Preferential Issue Venkata Rao Sadhanala Managing Director Statement of Deviation / Variation in utilization of funds raised: Annexure A Objects for which funds have been raised: Venkata Rao Sadhanala Managing Director
Venmax Drugs & Pharmaceuticals Ltd. on 6ix
Earlier from Venmax Drugs & Pharmaceuticals
- Unaudited Financial Results For The Quarter Ended June 30, 2026.
- Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2026.
- Venmax Drugs & Pharmaceuticals Ltd. Press Release Aug 01 2026
- Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2026.
- Venmax Drugs & Pharmaceuticals Ltd. Press Release Jul 29 2026
Later from Venmax Drugs & Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Venmax Drugs & Pharmaceuticals Ltd. Press Release Aug 08 2026
- Board Meeting Intimation for Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
- Venmax Drugs & Pharmaceuticals Ltd. Press Release Aug 24 2026
- Board Meeting Outcome for Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Follow Venmax Drugs & Pharmaceuticals into a list and get an email when it puts out news.
Follow Venmax Drugs & Pharmaceuticals